‘Precautionary’ recall of breast cancer medication batch

A batch of Tamoxifen 20mg film-coated tablets has been recalled as a precautionary measure following the identification of a ‘dissolution failure’ during stability testing.

Wockhardt UK Limited has recalled batch number HZ10030 (expiry date: 30/04/2027), distributed in packs of 30 tablets.

Related Article: Travellers beware: what pharmacists need to know about global travel

The batch of medication, used primarily to treat breast cancer, was first distributed on 22 August 2024.

In a recall alert issued by the Medicines and Healthcare products Regulatory Agency (MHRA) on Monday, pharmacists have been advised to immediately cease supplying the affected batch, quarantine remaining stocks, and return them via approved supplier processes.

The MHRA explained that patients should continue to take medicines as prescribed by their healthcare professional.

‘The recall is being actioned at the pharmacy and wholesaler level as a precautionary measure,’ the alert said.

Related Article: Beyond the scales: reframing eating disorder recognition in primary care

‘No complaints of harm or lack of efficacy have been received from patients regarding this batch.’

Patients who experience adverse reactions or have any questions about the medication are advised to seek medical attention, the MHRA added.

Related Article: Sharp rise in diabetes cases prompts call for better postnatal support

Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

Also on Monday, a batch of Omeprazole 20 mg/15 ml oral solution was recalled as a precautionary measure following a customer complaint indicating ‘precipitation and discoloration’ of the product in the bottles.